Just out @NEJM from @DhruvKhullar et al. The structure of rewards (and costs) in pharmaceutical drug development. We introduce the 'reward box' interactive graphic to see how the elements interplay, how specific policies affect it.https://www.nejm.org/doi/full/10.1056/NEJMhpr1911004?query=featured_home …
-
Prikaži ovu nit
-
Here's a link to the interactive graphic:https://www.nejm.org/doi/full/10.1056/NEJMhpr1911004?query=featured_home …
1 reply 2 proslijeđena tweeta 6 korisnika označava da im se sviđaPrikaži ovu nit -
And here is a sample of 3 policies we describe and how they alter the Reward Box shape and thus the risk and reward of developing particular types of drugs:pic.twitter.com/lJd213pOVo
1 reply 6 proslijeđenih tweetova 8 korisnika označava da im se sviđaPrikaži ovu nit -
Graphic labeled the 'Reward Box' to enable the double entendre sub-header in the title. But also, we want policymakers to in fact 'think inside the box'. The market is a policy construct, it is not 'free'. The industry sees it all of a piece, policy makers should too.
0 proslijeđenih tweetova 3 korisnika označavaju da im se sviđaPrikaži ovu nit
Pharma market is not “free” but monopoly-based business model. The story of Allergan shows how corporate power harms public health. It shows the harm produced by incentives in a monopoly-based business model.https://www.citizen.org/article/by-any-means-necessary/ …
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.